NIH: ‘Plasma should not be considered standard of care’

NIH’s updated COVID-19 treatment guidelines offer a rebuke to FDA’s authorization of convalescent plasma, a decision that has drawn wide criticism from former FDA officials and other KOLs in the life sciences. 

“There are insufficient data to recommend either for or against the use of convalescent plasma for the treatment of COVID-19,”  NIH’s COVID-19 Treatment Guidelines Panel found. “Convalescent plasma should not be considered standard of care.”...